Amarin Corp. Plc (AMRN)
13.70
-0.14
(-1.05%)
USD |
NASDAQ |
Sep 02, 16:00
13.70
0.00 (0.00%)
After-Hours: 16:04
Amarin Research and Development Expense (TTM) : 16.15M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.15M |
| March 31, 2026 | 16.24M |
| December 31, 2025 | 16.82M |
| September 30, 2025 | 17.36M |
| June 30, 2025 | 17.86M |
| March 31, 2025 | 17.61M |
| December 31, 2024 | 17.85M |
| September 30, 2024 | 17.75M |
| June 30, 2024 | 18.27M |
| March 31, 2024 | 19.21M |
| December 31, 2023 | 19.33M |
| September 30, 2023 | 18.74M |
| June 30, 2023 | 19.35M |
| March 31, 2023 | 22.92M |
| December 31, 2022 | 27.18M |
| September 30, 2022 | 27.64M |
| June 30, 2022 | 29.70M |
| March 31, 2022 | 26.77M |
| December 31, 2021 | 26.44M |
| September 30, 2021 | 29.53M |
| June 30, 2021 | 32.39M |
| March 31, 2021 | 36.31M |
| December 31, 2020 | 37.19M |
| September 30, 2020 | 40.05M |
| June 30, 2020 | 38.84M |
| Date | Value |
|---|---|
| March 31, 2020 | 36.29M |
| December 31, 2019 | 33.67M |
| September 30, 2019 | 34.38M |
| June 30, 2019 | 39.65M |
| March 31, 2019 | 50.49M |
| December 31, 2018 | 55.01M |
| September 30, 2018 | 55.31M |
| June 30, 2018 | 51.96M |
| March 31, 2018 | 47.98M |
| December 31, 2017 | 46.49M |
| September 30, 2017 | 43.66M |
| June 30, 2017 | 45.33M |
| March 31, 2017 | 43.38M |
| December 31, 2016 | 45.91M |
| September 30, 2016 | 49.27M |
| June 30, 2016 | 49.85M |
| March 31, 2016 | 49.57M |
| December 31, 2015 | 48.48M |
| September 30, 2015 | 48.19M |
| June 30, 2015 | 49.68M |
| March 31, 2015 | 50.13M |
| December 31, 2014 | 50.52M |
| September 30, 2014 | 54.88M |
| June 30, 2014 | 57.33M |
| March 31, 2014 | 62.36M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Neurocrine Biosciences, Inc. | 1.131B |
| Alkermes Plc | 384.84M |
| Cellectis SA | 82.95M |
| Akari Therapeutics Plc | 4.869M |
| Liquidia Corp. | 54.95M |